Antilipemic agents
New Study Reveals Simvastatin Fails to Halt Disability Progression in Multiple Sclerosis Patients
Research from University College London (UCL) has shed light on the efficacy of simvastatin in treating secondary progressive multiple sclerosis (SPMS). Despite the promising results of its predecessor, the MS-STAT trial, the latest study, MS-STAT2, has found that simvastatin does not slow down disability progression in SPMS patients. The trial